Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma (original) (raw)

References

1. Atkins MB (1997) The treatment of metastatic melanoma with chemotherapy: biologics. Curr Opin Oncol 9:205
   CAS PubMed Google Scholar
2. Von Eschen KB, Mitchell MS (1997) Phase III trial of melacine melanoma theraccine versus combination chemotherapy in the treatment of stage IV melanoma. Melanoma Res 7:S51
   PubMed Google Scholar
3. Hersey P (2002) Advances in the non-surgical treatment of melanoma. Expert Opin Investig Drugs 11:75
   CAS PubMed Google Scholar
4. Steinman RM (1996) Dendritic cells and immune-based therapies. Exp Hematol 24:859
   CAS PubMed Google Scholar
5. Banchereau J, Paczesny S, Blanco P, Bennett L, Pascual V, Fay J, Palucka AK (2003) Dendritic cells: controllers of the immune system and a new promise for immunotherapy. Ann N Y Acad Sci 987:180
   CAS PubMed Google Scholar
6. Grabbe S, Bruvers S, Gallo RL, Knisely TL, Nazareno R, Granstein RD (1991) Tumor antigen presentation by murine epidermal cells. J Immunol 146:3656
   CAS PubMed Google Scholar
7. Cavanagh LL, Sluyter R, Henderson KG, Barnetson RS, Halliday GM (1996) Epidermal Langerhans’ cell induction of immunity against an ultraviolet-induced skin tumour. Immunology 87:475
   CAS PubMed Google Scholar
8. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB (1995) Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1:1297
   CAS PubMed Google Scholar
9. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr (1996) Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 183:283
   CAS PubMed Google Scholar
10. Zitvogel L, Mayordomo JI, Tjandrawan T, Deleo AB, Clarke MR, Lotze MT, Storkus WJ (1996) Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 183:87
    CAS PubMed Google Scholar
11. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328
    CAS PubMed Google Scholar
12. Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, van Den Driesch P, Brocker EB, Steinman RM, Enk A, Kampgen E, Schuler G (1999) Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190:1669
    CAS PubMed Google Scholar
13. Mackensen A, Herbst B, Chen JL, Kohler G, Noppen C, Herr W, Spagnoli GC, Cerundolo V, Lindemann A (2000) Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer 86:385
    CAS PubMed Google Scholar
14. Panelli MC, Wunderlich J, Jeffries J, Wang E, Mixon A, Rosenberg SA, Marincola FM (2000) Phase I study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J Immunother 23:487
    CAS PubMed Google Scholar
15. Chakraborty NG, Sporn JR, Tortora AF, Kurtzman SH, Yamase HY, Ergin MT, Mukherji B (1998) Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma. Cancer Immunol Immunother 47:58
    Article CAS PubMed Google Scholar
16. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N, Pineiro L, Steinman R, Fay J (2001) Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 61:6451
    CAS PubMed Google Scholar
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Nat Cancer Inst 92:205
    Article CAS PubMed Google Scholar
18. Hersey P (1997) Melanoma vaccines: prospects for the treatment of melanoma. Expert Opin Investig Drugs 6:267
    CAS Google Scholar
19. Valmori D, Fonteneau J-F, Lizana CM, Gervois N, Lienard D, Rimoldi D, Jongeneel V, Jotereau F, Cerottini J-C, Romero P (1998) Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol 160:1750
    CAS PubMed Google Scholar
20. Parkhurst MR, Salgaller ML, Southwood S, Robbins PF, Sette A, Rosenberg SA, Kawakami Y (1996) Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol 157:2539
    CAS PubMed Google Scholar
21. Skipper JCA, Hendrickson RC, Gulden PH, Brichard V, van Pel A, Chen Y, Shabanowitz J, Wolfel T, Slingluff CLJr, Boon T, Hunt DF, Engelhard VH (1996) An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 183:527
    CAS PubMed Google Scholar
22. Jaeger E, Ringhoffer M, Dienes HP, Arand M, Karbach J, Jager D (1996) Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer 67:54
    PubMed Google Scholar
23. Saleh FH, Crotty KA, Hersey P, Menzies SW (2001) Primary melanoma tumour regression associated with an immune response to the tumour-assocated antigen melan-A/MART-1. Int J Cancer 94:551
    Article CAS PubMed Google Scholar
24. Nijman HW, Houbiers JGA, Vierboom MPM, Van Der Burg SH, Drijfhout JW, D’Amaro J, Kenemans P, Melief CJM, Kast WM (1993) Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur J Immunol 23:1215
    CAS PubMed Google Scholar
25. Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA (1996) Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 56:4749
    CAS PubMed Google Scholar
26. Cao X, Sugita M, Van Der Wel N, Lai J, Rogers RA, Peters PJ, Brenner MB (2002) CD1 molecules efficiently present antigen in immature dendritic cells and traffic independently of MHC class II during dendritic cell maturation. J Immunol 169:4770
    PubMed Google Scholar
27. Corbi AL, Lopez-Rodriguez C (1997) CD11c integrin gene promoter activity during myeloid differentation. Leuk Lymphoma 25:415
    CAS PubMed Google Scholar
28. Smithers M, O’Connell K, MacFadyen S, Chambers M, Greenwood K, Boyce A, Abdul-Jabbar I, Barker K, Grimmett K, Walpole E, Thomas R (2003) Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen. Cancer Immunol Immunother 52:41
    CAS PubMed Google Scholar
29. Lee K-H, Panelli MC, Kim CJ, Riker AI, Bettinotti MP, Roden MM, Fetsch P, Abati A, Rosenberg SA, Marincola FM (1998) Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination. J Immunol 161:4183
    CAS PubMed Google Scholar
30. Clay TM, Hobeika AC, Mosca PJ, Lyerly HK, Morse MA (2001) Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin Cancer Res 7:1127
    CAS PubMed Google Scholar
31. Whiteside TL, Zhao Y, Tsukishiro T, Elder EM, Gooding W, Baar J (2003) Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma. Clin Cancer Res 9:641
    CAS PubMed Google Scholar
32. Yang S, Linette GP, Longerich S, Haluska FG (2002) Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp 100 peptide G209–2M is correlated to TCR avidity. J Immunol 169:531
    CAS PubMed Google Scholar
33. Monsurro V, Nagorsen D, Wang E, Provenzano M, Dudley ME, Rosenberg SA, Marincola FM (2002) Functional heterogeneity of vaccine-induced CD8(+) T cells. J Immunol 168:5933
    CAS PubMed Google Scholar
34. Morse MA, Clay TM, Mosca P, Lyerly HK (2002) Immunoregulatory T cells in cancer immunotherapy. Expert Opin Biol Ther 2:827
    CAS PubMed Google Scholar
35. Javia LR, Rosenberg SA (2003) CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. J Immunother 26:85
    Article CAS PubMed Google Scholar
36. Zehntner S, Townsend W, Parkes J, Schmidt C, Down M, Bell J, Mulligan R, O’Rourke M, Ellem K, Thomas R (1999) Tumor metastasis biopsy as a surrogate marker of response to melanoma immunotherapy. Pathology 31:116
    Article CAS PubMed Google Scholar
37. Labeur MS, Roters B, Pers B, Mehling A, Luger TA, Schwarz T, Grabbe S (1999) Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation. J Immunol 162:168
    CAS PubMed Google Scholar
38. Jonuleit H, Giesecke-Tuettenberg A, Tuting T, Thurner-Schuler B, Stuge TB, Paragnik L, Kandemir A, Lee PP, Schuler G, Knop J, Enk AH (2001) A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 93:243
    PubMed Google Scholar
39. Jonuleit H, Giesecke A, Kandemir A, Paragnik L, Knop J, Enk AH (2000) Induction of tumor peptide-specific cytotoxic T cells under serum-free conditions by mature human dendritic cells. Arch Dermatol 292:325
    Article CAS PubMed Google Scholar
40. Adema GJ, de Vries IJM, Bernsen M, van Muijen GNP, Scharenborg NM, Lesterhuis WJ, Punt CJA, Figdor CG (2002) Immunological and clinical responses in melanoma patients after treatment with peptide-loaded dendritic cells administered via different routes of immunization. 7th symposium on dendritic cells, September 2002 (Abstract 019)
41. de Vries IJM, Krooshoop JEB, Scharenborg NM, Lesterhuis WJ, Diepstra JHS, van Muijen GNP, Strijk SP, Ruers TJ, Boerman OC, Oyen WJG, Adema GJ, Punt CJA, Figdor CG (2003) Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 63:12
    PubMed Google Scholar
42. Mahnke K, Schmitt E, Bonifaz L, Enk AH, Jonuleit H (2002) Immature, but not inactive: the tolerogenic function of immature dendritic cells. Immunol Cell Biol 80:477
    Article PubMed Google Scholar
43. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N (2001) Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 193:233
    CAS PubMed Google Scholar
44. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH (2000) Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 192:1213
    Article CAS PubMed Google Scholar
45. Roncarolo M-G, Levings MK, Traversari C (2001) Differentiation of T regulatory cells by immature dendritic cells. J Exp Med 193:F5
    Article CAS PubMed Google Scholar
46. Ranieri E, Kierstead LS, Zarour H, Kirkwood JM, Lotze MT, Whites T, Storkus WJ (2000) Dendritic cell/peptide cancer vaccines: clinical responsivene and epitope spreading. Immunol Invest 29:121
    CAS PubMed Google Scholar
47. Shimizu K, Thomas EK, Giedlin M, Mule JJ (2001) Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein. Cancer Res 61:2618
    CAS PubMed Google Scholar
48. Millard AL, Ittelet D, Schooneman F, Bernard J (2003) Dendritic cell KLH loading requirements for efficient CD4(+) T-cell priming and help to peptide-specific cytotoxic T-cell response, in view of potential use in cancer vaccines. Vaccine 2:869
    Article Google Scholar
49. Shimizu K, Fields RC, Giedlin M, Mule JJ (1999) Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc Natl Acad Sci U S A 96:2268
    Article CAS PubMed Google Scholar
50. Portielje JE, Gratama JW, van Ojik HH, Stoter G, Kruit WH (2003) IL-12: a promising adjuvant for cancer vaccination. Cancer Immunol Immunother 52:133
    CAS PubMed Google Scholar
51. Asavaroengchai W, Kotera Y, Mule JJ (2002) Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc Natl Acad Sci U S A 99:931
    Article CAS PubMed Google Scholar
52. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber D, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Dura P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850
    Article CAS PubMed Google Scholar
53. Hersey P, Zhang XD (2001) How melanoma cells evade TRAIL-induced apoptosis. Nat Rev 1:142
    Article CAS Google Scholar
54. Hersey P, Zhang XD (2003) Overcoming resistance of cancer cells to apoptosis. J Cell Physiol 169:9
    Article Google Scholar
55. Schuler-Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S, Woerl P, Bender A, Feuerstein B, Fritsch PO, Romani N, Schuler G (2002) Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 195:1279
    Article CAS PubMed Google Scholar
56. Gajewsky TF, Fallarino F, Vogelzang N, Posner MC, Ashikari A, Sherman ML (1999) Effective melanoma antigen vaccination without dendritic cells (DC): A phase I study of immunization with Mage3 or Melan-A peptide-pulsed autologous PBMC plus RhIL-12. Proc ASCO 18:539a
    Google Scholar
57. Chang AE, Redman BG, Whitfield JR, Nickoloff BJ, Braun TM, Lee PP, Geiger JD, Mule JJ (2002) A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res 8:1021
    CAS PubMed Google Scholar
58. Lau R, Wang F, Jeffery G, Marty V, Kuniyoshi J, Bade E, Ryback ME, Weber J (2001) Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunother 24:66
    Google Scholar

Download references